Evidence map›Paper›PMID 32467347›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020

Leveraging Genome and Phenome-Wide Association Studies to Investigate Genetic Risk of Acute Lymphoblastic Leukemia.

Eleanor C Semmes, Jayaram Vijayakrishnan, Chenan Zhang, Jillian H Hurst, Richard S Houlston, Kyle M Walsh

Open access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. PleiotropicNeuro-oncology advances
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Eleanor C SemmesMedical Scientist Training Program, Duke University, Durham, North Carolina.ORCID 0000-0003-2595-1948
Jayaram VijayakrishnanDivision of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.ORCID 0000-0002-8284-2249
Chenan ZhangDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-1773-4441
Jillian H HurstChildren's Health and Discovery Initiative, Department of Pediatrics, Duke University, Durham, North Carolina.ORCID 0000-0001-5079-9920
Richard S HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.ORCID 0000-0002-5268-0242
Kyle M WalshChildren's Health and Discovery Initiative, Department of Pediatrics, Duke University, Durham, North Carolina. kyle.walsh@duke.edu.ORCID 0000-0002-5879-9981
Duke University · USInstitute of Cancer Research · GBUniversity of California, San Francisco · US

Funding

COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2M
Support for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5M
PHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL)R37CA036401 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI EVANS, WILLIAM E · 1987 to 2014
$9.7M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6M
Drug Resistant Pathways in Relapsed Acute Lymphoblastic Leukemia(ALL)R01CA140729 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L. · 2010 to 2020
$4.8M
Glucocorticoids in Lymphoblastic LeukemiaR01CA142665 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2020
$4.6M
Pharmacogenomics of Childhood Leukemia ALLR01CA036401 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI EVANS, WILLIAM E · 1985 to 2019
$3.6M
Pharmacogenomics of Racial Disparities in Childhood Leukemia OutcomesRC4CA156449 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2010
$1.7M
PDE4B and pharmacoethnicity of childhood leukemiaR21CA158568 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YANG, JUN J. · 2011 to 2012
$422k
NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA036401NCI NIH HHS R01 CA140729NCI NIH HHS R01 CA142665NCI NIH HHS R21 CA158568NCI NIH HHS R21 CA242439NCI NIH HHS R37 CA036401NCI NIH HHS RC4 CA156449NCI NIH HHS T32 CA151022NCI NIH HHS U10 CA098543NCI NIH HHS U24 CA114766NIGMS NIH HHS T32 GM007171NIGMS NIH HHS U01 GM092666Wellcome Trust 076113Wellcome Trust 085475
6 · The paper itself

Abstract

backgroundGenome-wide association studies (GWAS) of childhood cancers remain limited, highlighting the need for novel analytic strategies. We describe a hybrid GWAS and phenome-wide association study (PheWAS) approach to uncover genotype-phenotype relationships and candidate risk loci, applying it to acute lymphoblastic leukemia (ALL).

methodsPheWAS was performed for 12 ALL SNPs identified by prior GWAS and two control SNP-sets using UK Biobank data. PheWAS-traits significantly associated with ALL SNPs compared with control SNPs were assessed for association with ALL risk (959 cases, 2,624 controls) using polygenic score and Mendelian randomization analyses. Trait-associated SNPs were tested for association with ALL risk in single-SNP analyses, with replication in an independent case-control dataset (1,618 cases, 9,409 controls).

resultsPlatelet count was the trait most enriched for association with known ALL risk loci. A polygenic score for platelet count (223 SNPs) was not associated with ALL risk (

conclusionsIn our hybrid GWAS-PheWAS approach, we identify pleiotropic genetic variation contributing to ALL risk and platelet count. Three SNPs known to influence platelet count were reproducibly associated with ALL risk, implicating genomic regions containing IMPACT: Incorporating PheWAS data into association studies can leverage genetic pleiotropy to identify cancer risk loci, highlighting the utility of our novel approach.

Indexed as

Case-Control StudiesGenome-Wide Association StudyGenomicsGenotypeHumansPhenomicsPolymorphism, Single NucleotidePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Identifiers

PMID32467347
PMCPMC7415687
OpenAlexW3032127145

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.